XW0DXJ9
Introduction Mouth and Pharynx to New Technology Group 9 with Quizartinib Antineoplastic, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | D Mouth and Pharynx |
| Approach | X External |
| Device | J Quizartinib Antineoplastic |
| Qualifier | 9 New Technology Group 9 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Mouth and Pharynx
The mouth and pharynx together form the oral cavity and the muscular passage connecting it to the esophagus and larynx, structures involved in swallowing, airway protection, and initial digestion. Introduction procedures coded here under New Technology involve applying or instilling a novel substance into this region, which may be used for local therapeutic effect on mucosal tissue or to address conditions affecting swallowing or the upper aerodigestive tract. Because the mouth and pharynx are anatomically complex and functionally tied to both respiration and digestion, care must be taken during substance introduction to avoid aspiration or airway compromise. This code applies specifically when the agent used qualifies as New Technology rather than a standard topical or irrigating solution.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Quizartinib Antineoplastic
Quizartinib Antineoplastic denotes administration of an oral FLT3 inhibitor used in combination with chemotherapy for FLT3-ITD-positive acute myeloid leukemia. It works by blocking a mutated tyrosine kinase driving leukemic cell proliferation, distinguishing it from cytotoxic or radiopharmaceutical antineoplastics like melphalan or iobenguane I-131, which act through nonselective or radiation-based mechanisms rather than targeted kinase inhibition.
Qualifier: New Technology Group 9
Group 9 is the seventh-position qualifier used in the New Technology section to mark a device, substance, or technique as belonging to the 2022 annual cohort of new technology add-on codes. It has no clinical meaning of its own beyond that vintage tag, so coders rely on the specific table and body system to know what procedure it applies to. It is distinguished from Group 8 and Group 10 purely by the fiscal year the technology was approved for separate identification.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.